Table 1.
Characteristics of study cohort.
| Patient cohort characteristics | |
|---|---|
| Total number of cases | 110 |
| Female | 37 (33.6%) |
| Male | 73 (66.4%) |
| Baseline characteristics | |
| Age (years) | 62 (22-84) |
| BMI | 26.6 (15.4-54.6) |
| Stage III | 8 (7.3%) |
| Stage IV | 102 (92.7%) |
| Liver metastases present | 30 (27.3%) |
| CMV seropositive | 52 (47.3%) |
| ANA positive | 65 (59.1%) |
| Pretreatment | |
| None | 3 (2.7%) |
| Surgical excision | 102 (92.7%) |
| Radiosurgery | 3 (2.7%) |
| Radiation | 42 (38.2%) |
| Monotherapy | 17 (15.5%) |
| IFNa therapy | 9 (8.2%) |
| Braf/Mek inhibitor therapy | 21 (19.1%) |
| T-VEC therapy | 7 (6.4%) |
| Chemotherapy | 6 (5.5%) |
| Rounds of Ipi/Nivo | |
| 1 round | 13 (11.8%) |
| 2 rounds | 24 (21.8%) |
| 3 rounds | 20 (18.2%) |
| 4 rounds | 53 (48.2%) |
| Complications | |
| Hepatitis | 48 (43.6%) |
| Colitis | 40 (36.4%) |
| Thyroiditis | 41 (37.3%) |
| No complication | 23 (20.9%) |
| 1 complication | 50 (45.5%) |
| 2 complications | 32 (29.1%) |
| 3 complications | 5 (4.5%) |
110 patients with Stage III/IV melanoma were enrolled into the study cohort. For Age and BMI, median values were calculated. Minimum and maximum values are given in brackets. Baseline characteristics were obtained before start of Ipi/Nivo therapy.